Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Inclusion Criteria:

* Histologically confirmed invasive adenocarcinoma of the breast or inflammatory breast cancer, with an interval between definitive breast surgery and study registration of \<60 days.
* Definitive surgical treatment must be either mastectomy or breast-conserving therapy with axillary lymph node dissection for operable breast cancer (pT1 4 \[including inflammatory breast cancer\], pN0 3, and M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin.
* Patients with ≥1 axillary lymph node containing metastatic adenocarcinoma measuring \>0.2 mm, OR lymph node-negative patients with high-risk features
* Patients with HER2/neu positive or negative tumors (HER2 positivity must be documented by FISH positivity or IHC 3+).
* Patients who are to receive trastuzumab must have normal cardiac function (MUGA \[cardiac ejection fraction \>50%, or greater than or equal to the institutional lower limit of normal\], or echocardiogram \[ECHO\] within institutional normal limits).
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
* Patients who are either chemotherapy naïve, or who have received prior chemotherapy \>5 years ago.
* Patients with previous invasive cancers (including breast cancer) eligible only if treated \>5 years prior to entering this study, and show no evidence of recurrent disease.
* Adequate bone marrow function
* Adequate liver function,
* Adequate renal function,
* Patients of childbearing potential must use an effective method of contraception that is acceptable to their study physician from the time of signing informed consent until at least 3 months after the last dose of protocol treatment, and must have a negative pre study serum pregnancy test.
* Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.
* MammoSite® brachytherapy radiation accepted when performed immediately following surgery and prior to receiving chemotherapy.
* Patients with bilateral, synchronous breast cancer, provided that one primary tumor meets the inclusion criteria.

Exclusion Criteria:

* Patients who are pregnant or breastfeeding.
* M1 metastatic disease.
* Patients requiring neoadjuvant chemotherapy.
* Life expectancy of greater than 6 months.
* History of cardiac disease, with a New York Heart Association (NYHA) Class II or greater CHF
* Myocardial infarction (MI) or unstable angina in the past 12 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment, any history of stroke or transient ischemic attack at any time, clinically significant peripheral vascular disease, or evidence of a bleeding diathesis or coagulopathy.
* Any investigational agent within 30 days of receiving the first dose of study drug.
* Treatment with prior trastuzumab or bevacizumab therapy.
* Concurrent treatment with any other anti-cancer therapy is not permitted.
* History of significant psychiatric disorders.
* History of active, uncontrolled infection.
* A serious, non-healing wound, ulcer, or bone fracture.
* Any other diseases, metabolic dysfunction, findings from a physical examination, or clinical laboratory test results that give reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results or that renders the patient at high risk from treatment complications.